Business Context and Reporting Period
NanoViricides, Inc. (NNVC), a Nevada corporation, filed this Form 8-K on July 31, 2020. The report details the entry into a material definitive agreement to establish an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization of an ATM Offering with an aggregate offering price of up to $50 million.
- Offering Size: Up to $50 million in common stock.
- Commission Rate: Up to 3.5% of the gross sales price per share sold.
- Expense Reimbursement: Up to $50,000 for legal counsel fees and disbursements.
- Quarterly Retainer: Up to $2,500 per quarter for Sales Agents' legal fees.
Material Changes
The material change reported is the execution of an At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Kingswood Capital Markets. This agreement allows the company to sell shares of common stock from time to time through the sales agents based on market conditions and company instructions. No sales are guaranteed under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The company stated that actual sales will depend on market conditions, the trading price of its common stock, capital needs, and determinations regarding appropriate funding sources. The company is not obligated to make any sales.
Risks and Contingencies: The filing explicitly states that the company cannot provide assurances that it will issue any shares pursuant to the agreement. The offering is subject to the company's effective shelf registration statement on Form S-3.
Investor Verification Checklist
- Verify the current trading price of NNVC common stock to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Monitor subsequent filings to determine if and when shares are actually issued under the ATM program.
- Check the company's cash position in the most recent 10-Q or 10-K to understand the immediate capital need driving this facility.